Abstract
Cortical thickness may be useful as a treatment response predictor in first-episode (FE) patients with schizophrenia, although this possibility has been scarcely assessed. In this study we assessed the possible relation between cortical thickness in regions of interest selected because of previously reported structural alterations in schizophrenia and clinical and cognitive changes after two years of treatment with risperidone or clozapine in 31 neuroleptic-naïve FE patients with schizophrenia (16 of them treated with clozapine and 15 with risperidone). Using the last-observation-carried-forward (LOCF), a larger improvement in positive, negative and total symptoms was predicted by the amount of baseline cortical thinning in the right prefrontal cortex (pars orbitalis). After two years of treatment, cognitive status was reassessed in the 17 patients (11 on clozapine) who had not dropped out. Working memory improvement after reassessment was associated with a greater baseline cortical thinning in the left prefrontal cortex (pars orbitalis), and verbal memory improvement with a greater baseline cortical thinning in the left pars triangularis. Significant but weak cortical thickness decrease from baseline to follow-up was observed in patients in comparison to controls (left pars triangularis and opercularis, and left caudal middle frontal areas). These results may support a positive predictive role for cortical thinning in the frontal region with regard to clinical and cognitive improvement with clozapine and risperidone in FE patients with schizophrenia.
Original language | English |
---|---|
Pages (from-to) | 223-229 |
Number of pages | 7 |
Journal | Schizophrenia Research |
Volume | 158 |
Issue number | 1-3 |
DOIs | |
Publication status | Published - Sept 2014 |
Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by the Spanish Ministry of Health ‘Ayudas para el Fomento de la Traslación de la Aplicación Terapéutica de Medicamentos Huérfanos y Terapias Avanzadas’ (grant number: TRA-035) and Instituto de Salud Carlos III (grant number: PI-060219).